List of Tables
Table 1. Global Anti-VEGF Therapeutic Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Anti-VEGF Therapeutic Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Anti-VEGF Therapeutic Market Competitive Situation by Manufacturers in 2024
Table 4. Global Anti-VEGF Therapeutic Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Anti-VEGF Therapeutic Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Anti-VEGF Therapeutic Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Anti-VEGF Therapeutic Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Anti-VEGF Therapeutic Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Anti-VEGF Therapeutic, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Anti-VEGF Therapeutic, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Anti-VEGF Therapeutic, Product Type & Application
Table 12. Global Key Manufacturers of Anti-VEGF Therapeutic, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Anti-VEGF Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGF Therapeutic as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Anti-VEGF Therapeutic Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Anti-VEGF Therapeutic Sales by Region (2020-2025) & (K Units)
Table 18. Global Anti-VEGF Therapeutic Sales Market Share by Region (2020-2025)
Table 19. Global Anti-VEGF Therapeutic Sales by Region (2026-2031) & (K Units)
Table 20. Global Anti-VEGF Therapeutic Sales Market Share by Region (2026-2031)
Table 21. Global Anti-VEGF Therapeutic Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Anti-VEGF Therapeutic Revenue Market Share by Region (2020-2025)
Table 23. Global Anti-VEGF Therapeutic Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Anti-VEGF Therapeutic Revenue Market Share by Region (2026-2031)
Table 25. North America Anti-VEGF Therapeutic Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Anti-VEGF Therapeutic Sales by Country (2020-2025) & (K Units)
Table 27. North America Anti-VEGF Therapeutic Sales by Country (2026-2031) & (K Units)
Table 28. North America Anti-VEGF Therapeutic Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Anti-VEGF Therapeutic Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Anti-VEGF Therapeutic Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Anti-VEGF Therapeutic Sales by Country (2020-2025) & (K Units)
Table 32. Europe Anti-VEGF Therapeutic Sales by Country (2026-2031) & (K Units)
Table 33. Europe Anti-VEGF Therapeutic Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Anti-VEGF Therapeutic Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Anti-VEGF Therapeutic Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Anti-VEGF Therapeutic Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Anti-VEGF Therapeutic Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Anti-VEGF Therapeutic Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Anti-VEGF Therapeutic Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Anti-VEGF Therapeutic Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Anti-VEGF Therapeutic Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Anti-VEGF Therapeutic Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Anti-VEGF Therapeutic Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Anti-VEGF Therapeutic Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Anti-VEGF Therapeutic Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Anti-VEGF Therapeutic Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Anti-VEGF Therapeutic Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Anti-VEGF Therapeutic Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Anti-VEGF Therapeutic Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Anti-VEGF Therapeutic Sales (K Units) by Type (2020-2025)
Table 51. Global Anti-VEGF Therapeutic Sales (K Units) by Type (2026-2031)
Table 52. Global Anti-VEGF Therapeutic Sales Market Share by Type (2020-2025)
Table 53. Global Anti-VEGF Therapeutic Sales Market Share by Type (2026-2031)
Table 54. Global Anti-VEGF Therapeutic Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Anti-VEGF Therapeutic Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Anti-VEGF Therapeutic Revenue Market Share by Type (2020-2025)
Table 57. Global Anti-VEGF Therapeutic Revenue Market Share by Type (2026-2031)
Table 58. Global Anti-VEGF Therapeutic Price (US$/Unit) by Type (2020-2025)
Table 59. Global Anti-VEGF Therapeutic Price (US$/Unit) by Type (2026-2031)
Table 60. Global Anti-VEGF Therapeutic Sales (K Units) by Application (2020-2025)
Table 61. Global Anti-VEGF Therapeutic Sales (K Units) by Application (2026-2031)
Table 62. Global Anti-VEGF Therapeutic Sales Market Share by Application (2020-2025)
Table 63. Global Anti-VEGF Therapeutic Sales Market Share by Application (2026-2031)
Table 64. Global Anti-VEGF Therapeutic Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Anti-VEGF Therapeutic Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Anti-VEGF Therapeutic Revenue Market Share by Application (2020-2025)
Table 67. Global Anti-VEGF Therapeutic Revenue Market Share by Application (2026-2031)
Table 68. Global Anti-VEGF Therapeutic Price (US$/Unit) by Application (2020-2025)
Table 69. Global Anti-VEGF Therapeutic Price (US$/Unit) by Application (2026-2031)
Table 70. Regeneron Pharmaceuticals Company Information
Table 71. Regeneron Pharmaceuticals Description and Business Overview
Table 72. Regeneron Pharmaceuticals Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Regeneron Pharmaceuticals Anti-VEGF Therapeutic Product
Table 74. Regeneron Pharmaceuticals Recent Developments/Updates
Table 75. Bayer Company Information
Table 76. Bayer Description and Business Overview
Table 77. Bayer Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Bayer Anti-VEGF Therapeutic Product
Table 79. Bayer Recent Developments/Updates
Table 80. Novartis Company Information
Table 81. Novartis Description and Business Overview
Table 82. Novartis Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Novartis Anti-VEGF Therapeutic Product
Table 84. Novartis Recent Developments/Updates
Table 85. Roche Company Information
Table 86. Roche Description and Business Overview
Table 87. Roche Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Roche Anti-VEGF Therapeutic Product
Table 89. Roche Recent Developments/Updates
Table 90. Biogen Company Information
Table 91. Biogen Description and Business Overview
Table 92. Biogen Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Biogen Anti-VEGF Therapeutic Product
Table 94. Biogen Recent Developments/Updates
Table 95. Pfizer Company Information
Table 96. Pfizer Description and Business Overview
Table 97. Pfizer Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Pfizer Anti-VEGF Therapeutic Product
Table 99. Pfizer Recent Developments/Updates
Table 100. Coherus BioSciences Company Information
Table 101. Coherus BioSciences Description and Business Overview
Table 102. Coherus BioSciences Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Coherus BioSciences Anti-VEGF Therapeutic Product
Table 104. Coherus BioSciences Recent Developments/Updates
Table 105. Amgen Company Information
Table 106. Amgen Description and Business Overview
Table 107. Amgen Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Amgen Anti-VEGF Therapeutic Product
Table 109. Amgen Recent Developments/Updates
Table 110. Bausch Health Companies Company Information
Table 111. Bausch Health Companies Description and Business Overview
Table 112. Bausch Health Companies Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Bausch Health Companies Anti-VEGF Therapeutic Product
Table 114. Bausch Health Companies Recent Developments/Updates
Table 115. Viatris Company Information
Table 116. Viatris Description and Business Overview
Table 117. Viatris Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Viatris Anti-VEGF Therapeutic Product
Table 119. Viatris Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Anti-VEGF Therapeutic Distributors List
Table 123. Anti-VEGF Therapeutic Customers List
Table 124. Anti-VEGF Therapeutic Market Trends
Table 125. Anti-VEGF Therapeutic Market Drivers
Table 126. Anti-VEGF Therapeutic Market Challenges
Table 127. Anti-VEGF Therapeutic Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
Table 131. Authors List of This Report
List of Figures
Figure 1. Product Picture of Anti-VEGF Therapeutic
Figure 2. Global Anti-VEGF Therapeutic Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Anti-VEGF Therapeutic Market Share by Type: 2024 & 2031
Figure 4. Aflibercept (Eylea) Product Picture
Figure 5. Ranibizumab (Lucentis) Product Picture
Figure 6. Brolucizumab (Beovu) Product Picture
Figure 7. Others Product Picture
Figure 8. Global Anti-VEGF Therapeutic Market Value by Application (2020-2031) & (US$ Million)
Figure 9. Global Anti-VEGF Therapeutic Market Share by Application: 2024 & 2031
Figure 10. Macular Edema
Figure 11. Diabetic Retinopathy
Figure 12. Retinal Vein Occlusion
Figure 13. Age-related Macular Degeneration
Figure 14. Others
Figure 15. Global Anti-VEGF Therapeutic Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Anti-VEGF Therapeutic Market Size (2020-2031) & (US$ Million)
Figure 17. Global Anti-VEGF Therapeutic Sales (2020-2031) & (K Units)
Figure 18. Global Anti-VEGF Therapeutic Average Price (US$/Unit) & (2020-2031)
Figure 19. Anti-VEGF Therapeutic Report Years Considered
Figure 20. Anti-VEGF Therapeutic Sales Share by Manufacturers in 2024
Figure 21. Global Anti-VEGF Therapeutic Revenue Share by Manufacturers in 2024
Figure 22. Global 5 and 10 Largest Anti-VEGF Therapeutic Players: Market Share by Revenue in Anti-VEGF Therapeutic in 2024
Figure 23. Anti-VEGF Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 24. Global Anti-VEGF Therapeutic Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 25. North America Anti-VEGF Therapeutic Sales Market Share by Country (2020-2031)
Figure 26. North America Anti-VEGF Therapeutic Revenue Market Share by Country (2020-2031)
Figure 27. United States Anti-VEGF Therapeutic Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Canada Anti-VEGF Therapeutic Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. Europe Anti-VEGF Therapeutic Sales Market Share by Country (2020-2031)
Figure 30. Europe Anti-VEGF Therapeutic Revenue Market Share by Country (2020-2031)
Figure 31. Germany Anti-VEGF Therapeutic Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. France Anti-VEGF Therapeutic Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. U.K. Anti-VEGF Therapeutic Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Italy Anti-VEGF Therapeutic Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Russia Anti-VEGF Therapeutic Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Asia Pacific Anti-VEGF Therapeutic Sales Market Share by Region (2020-2031)
Figure 37. Asia Pacific Anti-VEGF Therapeutic Revenue Market Share by Region (2020-2031)
Figure 38. China Anti-VEGF Therapeutic Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Japan Anti-VEGF Therapeutic Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. South Korea Anti-VEGF Therapeutic Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. India Anti-VEGF Therapeutic Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Australia Anti-VEGF Therapeutic Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. China Taiwan Anti-VEGF Therapeutic Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Southeast Asia Anti-VEGF Therapeutic Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Latin America Anti-VEGF Therapeutic Sales Market Share by Country (2020-2031)
Figure 46. Latin America Anti-VEGF Therapeutic Revenue Market Share by Country (2020-2031)
Figure 47. Mexico Anti-VEGF Therapeutic Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Brazil Anti-VEGF Therapeutic Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Argentina Anti-VEGF Therapeutic Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Middle East and Africa Anti-VEGF Therapeutic Sales Market Share by Country (2020-2031)
Figure 51. Middle East and Africa Anti-VEGF Therapeutic Revenue Market Share by Country (2020-2031)
Figure 52. Turkey Anti-VEGF Therapeutic Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Saudi Arabia Anti-VEGF Therapeutic Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. UAE Anti-VEGF Therapeutic Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Global Sales Market Share of Anti-VEGF Therapeutic by Type (2020-2031)
Figure 56. Global Revenue Market Share of Anti-VEGF Therapeutic by Type (2020-2031)
Figure 57. Global Anti-VEGF Therapeutic Price (US$/Unit) by Type (2020-2031)
Figure 58. Global Sales Market Share of Anti-VEGF Therapeutic by Application (2020-2031)
Figure 59. Global Revenue Market Share of Anti-VEGF Therapeutic by Application (2020-2031)
Figure 60. Global Anti-VEGF Therapeutic Price (US$/Unit) by Application (2020-2031)
Figure 61. Anti-VEGF Therapeutic Value Chain
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
